Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi Sankyo

This article was originally published in PharmAsia News

Executive Summary

ArQule signed a two-part deal with Daiichi Sankyo Nov. 10 that gives the biotech important non-dilutive funding as well as validation for its discovery platform. In exchange for broad commercialization rights to ArQule's lead compound, the Phase II oncologic ARQ 197, Daiichi will pay $75 million in upfront funding along with up to $560 million in potential milestones
Advertisement

Related Content

Daiichi Sankyo And ArQule Expand Collaboration On Heels Of Positive ARQ 197 News
Daiichi Sankyo And ArQule Expand Collaboration On Heels Of Positive ARQ 197 News
Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications
Kyowa Hakko Kirin Pins Rebound On KW-0761 For Oncology And Allergy Indications
ArQule Gets $30 Million Up Front From Kyowa In Oncology Deal
ArQule Gets $30 Million Up Front From Kyowa In Oncology Deal
Advertisement
UsernamePublicRestriction

Register

SC067160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel